Oral metabolic franchise, a broader portfolio of oral small molecule candidates targeting metabolic disease beyond the lead GLP-1 program Recent Highlights: In May 2026, Structure reported positive end-of-Phase 2 feedback from the FDA for aleniglipron, clearing the way to begin a Phase 3 registrational program for chronic weight management in Q3 2026
Weekly self-injection under the skin (subcutaneous) Gradual dose increase to minimize side effects Regular follow-ups to monitor progress and adjust treatment Support with nutrition and lifestyle coaching Common Side Effects Nausea Diarrhea or constipation Mild stomach discomfort Side effects usually lessen after the first few weeks
Retatrutide (GLP3) is a triple agonist adding glucagon for energy expenditure and fat burning, with phase 2/3 trials showing 2428.7% average weight loss over 4868 weekspotentially double semaglutides impact. What weight loss results have retatrutide shown in trials
As the new obesity pharmacotherapies will lead up to 1525% mean WL, intensive lifestyle interventions may provide small additional WL benefit to these treatments [11, 106]
For some patients, a GLP-1 or related medication may be appropriate
Which End User leads the market
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
